Q/C TECHNOLOGIES, INC.
QCLS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for QCLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QCLS
Q/C TECHNOLOGIES, INC. (QCLS) is a biotechnology company transitioning its primary focus to laser-based computing while retaining legacy Isomyosamine and Supera-CBD therapeutic platforms, with no current product revenue and a need for substantial additional funding.
Key risk: No product revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$19.2M
Cash Runway
17.6 moLead Asset
isomyosamine (Phase 2)
Next Catalyst
Phase3_Topline · Dec 30, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 catalysts for Q/C TECHNOLOGIES, INC..
Q/C TECHNOLOGIES, INC. (QCLS) is a biotechnology company transitioning its primary focus to laser-based computing while retaining legacy Isomyosamine and Supera-CBD therapeutic platforms, with no current product revenue and a need for substantial additional funding.
- Company is shifting primary resources to laser-based computing, while evaluating strategic alternatives for legacy Isomyosamine and Supera-CBD platforms [sec_mda · as of 2026-08-12].
- As of June 30, 2026, cash and equivalents were $0.3M, with shareholders' equity of $21.8M and a net loss of $6.6M for the period [sec].
- Accumulated deficit stood at $145.7M as of March 31, 2026 [sec_mda · as of 2026-05-15].
- Company expects no revenue from product sales unless and until clinical development and regulatory approval are achieved for its therapeutic candidates [sec_mda · as of 2025-08-19].
- Future liquidity is expected to come from exercise of outstanding warrants and equity or debt financings [sec_mda · as of 2026-05-15].
What works
- Company retains ownership of Isomyosamine and Supera-CBD platforms, which may have residual value through potential divestiture, partnering, or licensing [sec_mda · as of 2026-08-12].
- As of March 31, 2026, the company had working capital of $10.0M and stockholders' equity of $20.7M, providing some near-term financial cushion [sec_mda · as of 2026-05-15].
- Company is actively pursuing a new strategic direction in laser-based computing, which could open new revenue streams if successful [sec_mda · as of 2026-08-12].
What to weigh
- Company has no product revenue and expects none until clinical development and regulatory approval are achieved, which is a lengthy and uncertain process [sec_mda · as of 2025-08-19].
- Cash and equivalents were only $0.3M as of June 30, 2026, indicating very limited liquidity [sec].
- Accumulated deficit of $145.7M as of March 31, 2026 reflects a history of significant losses [sec_mda · as of 2026-05-15].
- Company will need substantial additional funding to support both laser-based computing operations and legacy pharmaceutical assets, with no guarantee of raising capital on acceptable terms [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Company is shifting focus to laser-based computing and evaluating strategic alternatives for legacy platforms.
“Although our primary resources are now directed toward laser-based computing, we continue to own our historical Isomyosamine and Supera-CBD therapeutic platforms. We are evaluating strategic alternatives for these programs, including potential divestiture, partnering or licensing transactions intended to maximize their residual value.”
SEC MD&A · August 12, 2026
Company has no product revenue and will not generate any unless clinical development and regulatory approval are successful.
“We will not generate revenue from product sales unless and until we successfully complete clinical development, obtain regulatory approval for, and successfully commercialize our Isomyosamine and Supera-CBD product candidates.”
SEC MD&A · August 19, 2025
Company needs substantial additional funding.
“As a result of anticipated expenditures in both our new laser-based computing operations and our efforts to preserve and monetize our legacy pharmaceutical assets, we will need substantial additional funding to support our continuing operations and pursue our growth strategy.”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2026-12-30 · Phase 3 Topline: An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of L — Topline data from this Phase 3 study could provide key efficacy and safety readout for the therapeutic candidate.
- 2028-10-28 · Phase 3 Topline: An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of L — A later Phase 3 topline readout may provide additional data on the therapeutic candidate's profile.
Risks & what to watch (4)›
Key risks
- No product revenue — Company has no revenue from product sales and will not until clinical development and regulatory approval are achieved [sec_mda · as of 2025-08-19].
- Limited cash runway — Cash and equivalents were only $0.3M as of June 30, 2026, indicating very limited liquidity [sec].
- Need for additional capital — Company requires substantial additional funding for both laser-based computing and legacy assets, with no guarantee of raising capital on acceptable terms [sec_mda · as of 2026-08-12].
- Accumulated losses — Accumulated deficit of $145.7M as of March 31, 2026 reflects a history of significant losses [sec_mda · as of 2026-05-15].
What to watch
- Progress of laser-based computing operations and any revenue generation from this new direction [sec_mda · as of 2026-08-12].
- Outcome of strategic alternatives evaluation for Isomyosamine and Supera-CBD platforms, including potential divestiture or licensing [sec_mda · as of 2026-08-12].
- Ability to raise additional capital through warrant exercises or equity/debt financings [sec_mda · as of 2026-05-15].
- Clinical development milestones for Isomyosamine and Supera-CBD, if any, and regulatory approval progress [sec_mda · as of 2025-08-19].
Sources: SEC MD&A · Generated August 13, 2026 · How we verify sources →
Run Q/C TECHNOLOGIES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Q/C TECHNOLOGIES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
17.6 months
D/E 0.24 · 0% dilution
Lead: Phase 2
2 candidates
2 upcoming, next in ~122d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$1.9M
| Holder | Shares | Value |
|---|---|---|
| quinn opportunity partners llc | 211,390 | $729K |
| jane street group, llc | 126,188 | $435K |
| vanguard capital management llc | 75,022 | $259K |
| adar1 capital management, llc | 50,000 | $173K |
| geode capital management, llc | 47,390 | $163K |
| dimensional fund advisors lp | 19,058 | $66K |
| vanguard fiduciary trust co | 15,555 | $54K |
| state street corp | 12,905 | $45K |
| sunbelt securities, inc. | 1,750 | $6K |
| tower research capital llc (trc) | 1,593 | $5K |
Showing top 10 of 17 institutional holders of Q/C TECHNOLOGIES, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 13, 2026- % of float
- 91.5%
- Days to cover
- 3.7
- Shares short
- 1,331,165
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QCLS short interestFrequently asked questions
What is the AI investment thesis for Q/C TECHNOLOGIES, INC.?
Q/C TECHNOLOGIES, INC. (QCLS) is a biotechnology company transitioning its primary focus to laser-based computing while retaining legacy Isomyosamine and Supera-CBD therapeutic platforms, with no current product revenue and a need for substantial additional funding.
What is Q/C TECHNOLOGIES, INC.'s lead drug candidate?
Q/C TECHNOLOGIES, INC.'s most advanced tracked candidate is isomyosamine (Phase 2) for sarcopenia, frailty, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease, Hashimoto thyroiditis.
What is Q/C TECHNOLOGIES, INC.'s next catalyst?
Q/C TECHNOLOGIES, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of L" — expected December 30, 2026.
Where is Q/C TECHNOLOGIES, INC. headquartered?
Q/C TECHNOLOGIES, INC. (QCLS) is headquartered in New York, NY, United States.
What therapeutic areas does Q/C TECHNOLOGIES, INC. focus on?
Q/C TECHNOLOGIES, INC. develops therapies across Neurology, Immunology, Pain, Musculoskeletal, Endocrinology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.